The management of older adults with pancreatic adenocarcinoma

John R. Ogden, Hao Xie, Wen Wee Ma, Joleen M. Hubbard

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Pancreatic cancer is the eleventh most common cancer, yet it is the third leading cause of mortality. It is also largely a disease of older adults, with the median age of 71 at diagnosis in the US, with <1% of diagnoses occurring prior to age 50. Current NCCN guidelines recommend surgery for localized disease, followed by adjuvant therapy and/or consideration of enrollment in a clinical trial. For metastatic disease, current guidelines recommend clinical trial enrollment or systemic chemotherapy based on results from the landmark ACCORD-11 and MPACT trials. However, these trials focused heavily on younger, more fit patients, with the ACCORD-11 trial excluding patients over age 75 and the MPACT trial having 92% of its patients with a Karnofsky performance score >80. This article summarizes the available evidence in current literature in regards to the best treatment options for older adults, who represent the majority of pancreatic cancer diagnoses.

Original languageEnglish (US)
Article number85
JournalGeriatrics (Switzerland)
Issue number4
StatePublished - Dec 1 2018


  • Disease management
  • Localized disease
  • Metastatic disease
  • Older adults
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Health(social science)
  • Aging
  • Gerontology
  • Geriatrics and Gerontology


Dive into the research topics of 'The management of older adults with pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this